MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY
| العنوان: | MBCL-26. FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY |
|---|---|
| المؤلفون: | Richard A. Cohn, Jordan R. Hansford, Murali Chintagumpala, Tim Hassall, Ute Bartels, Stewart J. Kellie, Lin Tong, Dong Anh Khuong Quang, Paul A. Northcott, Michael Fisher, Giles W. Robinson, Amar Gajjar, Geoffrey McCowage, Eric Bouffet, Colton Terhune, Kristin Schroeder, Shridharan Gururangan, Kyle S. Smith |
| المصدر: | Neuro-Oncology |
| بيانات النشر: | Oxford University Press (OUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, Medulloblastoma, Cancer Research, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, medicine.disease, Chemotherapy regimen, Time to recurrence, Internal medicine, Recurrent disease, Medulloblastoma (Clinical), AcademicSubjects/MED00300, Medicine, AcademicSubjects/MED00310, Neurology (clinical), medicine.symptom, business, Initial therapy, Anaplasia, First Recurrence |
| الوصف: | OBJECTIVE To evaluate differences in time to recurrence among molecular subgroups of medulloblastoma treated on a single protocol and to identify factors associated with survival after first recurrence. METHODS Time to recurrence following SJMB03 treatment was compared across methylation subgroups among relapsed patients. Therapies received subsequent to relapse were noted. Kaplan-Meier methods and log-rank tests were used for statistical analyses. RESULTS 74 of 330 medulloblastoma patients developed recurrence after initial therapy. (38 Standard-Risk; 36 High-Risk). The 2- and 5-year survival after first recurrence was 30.4% and 14.6% respectively. DNA methylation-based subgroups from initial diagnosis were SHH (n=14), Group 3 (n=24), Group 4 (n=26), and unclassified (n=8). None of the pts with WNT MB had recurrent disease. Median time to first recurrence was 1.23, 0.91, and 3.09 years in SHH, Group3, and Group 4 respectively. Group 4 patients had longer post-recurrence survival than others (p-value=0.0169). Clinical risk at diagnosis (p-value=0.337), anaplasia (p-value=0.4032), TP53 (p-value=0.1969), MYC (p-value=0.8967), and MYCN (p value = 0.9404) abnormalities were not associated with post progression survival. Patients who received any therapeutic modality (chemotherapy, re-radiation and second surgery) had longer survival and those who had all three (n=10) had the best outcome (p-value CONCLUSION Outcome after recurrence in medulloblastoma is dismal, however, association with subgroups is still present. Group 4 patients had a longer time to recurrence and post progression survival. No other prognostic factor at initial diagnosis was associated with outcome after recurrence. Patients who received all 3 types of conventional therapy had better survival. |
| تدمد: | 1523-5866 1522-8517 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::408f7df4310abf6472741f8d7649a218 https://doi.org/10.1093/neuonc/noaa222.502 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....408f7df4310abf6472741f8d7649a218 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15235866 15228517 |
|---|